Lai Rongtao, Li Xinjie, Zhang Jie, Chen Jun, Yang Changqing, Xie Wen, Yu Yuecheng, Guo Xiaoyan, Zhang Xinrong, Lu Guoliang, Han Xi'an, Xie Qing, Chen Chengwei, Shen Tao, Mao Yimin
Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
JHEP Rep. 2024 Apr 25;6(8):101102. doi: 10.1016/j.jhepr.2024.101102. eCollection 2024 Aug.
BACKGROUND & AIMS: Currently, there is limited knowledge on the clinical profile of drug-induced liver injury (DILI) in Chinese children. We aimed to assess the clinical characteristics, suspected drugs, and outcomes associated with pediatric DILI in China.
This nationwide, multicenter, retrospective study, conducted between 2012 and 2014, analyzed 25,927 cases of suspected DILI at 308 medical centers using the inpatient medical register system. Utilizing the Roussel Uclaf causality assessment method score, only patients with scores ≥6 or diagnosed with DILI by three experts after scoring <6 were included in the analysis. Among them, 460 cases met the EASL biochemical criteria. The study categorized children into three age groups: toddlers (≥30 days to <6 years old), school-age children (6 to <12 years old), and adolescents (12 to <18 years old).
Hepatocellular injury was the predominant clinical classification, accounting for 63% of cases, with 34% of these cases meeting Hy's law criteria. Adolescents comprised the majority of children with moderate/severe DILI (65%). Similarly, adolescents faced a significantly higher risk of severe liver injury compared to younger children (adjusted odd ratios 4.75, = 0.002). The top three most frequently prescribed drug classes across all age groups were antineoplastic agents (25.9%), antimicrobials (21.5%), and traditional Chinese medicine (13.7%). For adolescents, the most commonly suspected drugs were antitubercular drugs (22%) and traditional Chinese medicine (23%).
Adolescents are at a greater risk of severe and potentially fatal liver injury compared to younger children. Recognizing the risk of pediatric DILI is crucial for ensuring safe medical practices.
Drug-induced liver injury, a poorly understood yet serious cause of pediatric liver disease, encompasses a spectrum of clinical presentations, ranging from asymptomatic liver enzyme elevation to acute liver failure. This retrospective study, utilizing a large Chinese cohort of pediatric liver injury cases from 308 centers nationwide, characterized the major clinical patterns and suspected drugs in detail, revealing that adolescents are at a greater risk of severe liver injury compared to younger children. Vigilant care and careful surveillance of at-risk pediatric patients are crucial for physicians, researchers, patients, caregivers, and policymakers. Additional multicenter prospective studies are needed to evaluate the risk of hepatotoxicity in outpatients and hospitalized pediatric patients.
目前,关于中国儿童药物性肝损伤(DILI)的临床特征了解有限。我们旨在评估中国儿童DILI的临床特征、可疑药物及相关结局。
这项在2012年至2014年期间开展的全国性、多中心回顾性研究,使用住院病历系统分析了308家医疗中心的25927例疑似DILI病例。采用乌普萨拉监测中心因果关系评估方法评分,仅将评分≥6分或评分<6分后经三名专家诊断为DILI的患者纳入分析。其中,460例符合欧洲肝脏研究学会(EASL)生化标准。该研究将儿童分为三个年龄组:幼儿(≥30天至<6岁)、学龄儿童(6至<12岁)和青少年(12至<18岁)。
肝细胞损伤是主要的临床分类,占病例的63%,其中34%的病例符合Hy法则标准。青少年占中度/重度DILI儿童的大多数(65%)。同样,与年幼儿童相比,青少年发生严重肝损伤的风险显著更高(校正比值比4.75,P = 0.002)。所有年龄组中最常开具的前三类药物是抗肿瘤药(25.9%)、抗菌药(21.5%)和中药(13.7%)。对于青少年,最常怀疑的药物是抗结核药(22%)和中药(23%)。
与年幼儿童相比,青少年发生严重且可能致命的肝损伤风险更大。认识到儿童DILI的风险对于确保安全医疗实践至关重要。
药物性肝损伤是儿童肝病中一个了解不足但严重的病因,涵盖一系列临床表现,从无症状的肝酶升高到急性肝衰竭。这项回顾性研究利用了来自全国308个中心的大量中国儿童肝损伤病例队列,详细描述了主要临床模式和可疑药物,表明与年幼儿童相比,青少年发生严重肝损伤的风险更大。对高危儿科患者进行警惕的护理和仔细的监测对医生、研究人员、患者、护理人员和政策制定者至关重要。需要更多的多中心前瞻性研究来评估门诊和住院儿科患者的肝毒性风险。